Literature DB >> 17636412

Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines.

Michela Biancolella1, Alessandra Valentini, Daniela Minella, Lucia Vecchione, Franca D'Amico, Giovanni Chillemi, Paolo Gravina, Susana Bueno, Gianluca Prosperini, Alessandro Desideri, Giorgio Federici, Sergio Bernardini, Giuseppe Novelli.   

Abstract

Androgens play an important role in controlling the growth of the normal prostate gland and in the pathogenesis of benign prostate hyperplasia, and prostate cancer. Although testosterone is the main androgen secreted from the testes, dihydrotestosterone (DHT), a more potent androgen converted from testosterone by 5alpha-reductase isozymes, type I and II, is the major androgen in the prostate cells. The aim of this study is to investigate the cellular and molecular effects of dutasteride, a potent inhibitor of 5alpha-reductase type I and type II, in androgen-responsive (LNCaP) and androgen-unresponsive (DU145) human prostate cancer(PCa) cell lines. The expression pattern of 190 genes, selected on the basis of their proved or potential role in prostate cancerogenesis related to androgen signalling, were analysed using a low density home-made oligoarray (AndroChip 2). Our results show that dutasteride reduces cell viability and cell proliferation in both cell lines tested. AndroChip 2 gene signature identified in LNCaP a total of 11 genes differentially expressed (FC >or= +/-1.5). Eight of these genes, were overexpressed and three were underexpressed. Overexpressed genes included genes encoding for proteins involved in biosynthesis and metabolism of androgen (HSD17B1;HSD17B3;CYP11B2), androgen receptor and androgen receptor co-regulators (AR;CCND1), and signal transduction(ERBB2; V-CAM; SOS1) whereas, underexpressed genes (KLK3; KLK2; DHCR24) were androgen-regulated genes (ARGs). No differentially expressed genes were scored in DU145. Microarray data were confirmed by quantitative real-time PCR assay (QRT-PCR). These data offer a selective genomic signature for dutasteride treatment in prostate epithelial cells and provide important insights in prostate cancer pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636412     DOI: 10.1007/s10637-007-9070-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  27 in total

Review 1.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

Review 2.  The biology of hormone refractory prostate cancer. Why does it develop?

Authors:  J T Isaacs
Journal:  Urol Clin North Am       Date:  1999-05       Impact factor: 2.241

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Phenotypic and genotypic characterization of commonly used human prostatic cell lines.

Authors:  S Mitchell; P Abel; M Ware; G Stamp; E Lalani
Journal:  BJU Int       Date:  2000-05       Impact factor: 5.588

5.  Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue.

Authors:  P Negri-Cesi; A Poletti; A Colciago; P Magni; P Martini; M Motta
Journal:  Prostate       Date:  1998-03-01       Impact factor: 4.104

Review 6.  Androgen receptors in prostate cancer.

Authors:  Zoran Culig; Helmut Klocker; Georg Bartsch; Hannes Steiner; Alfred Hobisch
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

7.  Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes.

Authors:  Francoise de Longueville; Franck A Atienzar; Laurence Marcq; Simon Dufrane; Stéphanie Evrard; Lydia Wouters; Florence Leroux; Vincent Bertholet; Brigitte Gerin; Rhys Whomsley; Thierry Arnould; José Remacle; Mickael Canning
Journal:  Toxicol Sci       Date:  2003-07-25       Impact factor: 4.849

8.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

Authors:  Gerald Andriole; David Bostwick; Otis Brawley; Leonard Gomella; Michael Marberger; Donald Tindall; Sharon Breed; Matt Somerville; Roger Rittmaster
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

Review 9.  5alpha-reductase inhibitors/finasteride.

Authors:  E Stoner
Journal:  Prostate Suppl       Date:  1996

10.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

Authors:  R J Pietras; J Arboleda; D M Reese; N Wongvipat; M D Pegram; L Ramos; C M Gorman; M G Parker; M X Sliwkowski; D J Slamon
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

View more
  11 in total

Review 1.  Novel targets for prostate cancer chemoprevention.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

2.  Identification and analysis of the promoter region of the human DHCR24 gene: involvement of DNA methylation and histone acetylation.

Authors:  Joanna Drzewinska; Aurelia Walczak-Drzewiecka; Marcin Ratajewski
Journal:  Mol Biol Rep       Date:  2010-06-22       Impact factor: 2.316

3.  Genetic tests and genomic biomarkers: regulation, qualification and validation.

Authors:  Giuseppe Novelli; Cinzia Ciccacci; Paola Borgiani; Marisa Papaluca Amati; Eric Abadie
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

Review 4.  Neuroprotective effects of estrogens: the role of cholesterol.

Authors:  A Peri
Journal:  J Endocrinol Invest       Date:  2015-06-18       Impact factor: 4.256

5.  5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.

Authors:  Khalid Z Masoodi; Raquel Ramos Garcia; Laura E Pascal; Yujuan Wang; Hei M Ma; Katherine O'Malley; Kurtis Eisermann; Daniel H Shevrin; Holly M Nguyen; Robert L Vessella; Joel B Nelson; Rahul A Parikh; Zhou Wang
Journal:  Endocrinology       Date:  2013-05-13       Impact factor: 4.736

Review 6.  Molecular imaging of prostate cancer: a concise synopsis.

Authors:  Hossein Jadvar
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

7.  Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells.

Authors:  Mikhail G Dozmorov; Robert E Hurst; Daniel J Culkin; Bradley P Kropp; Mark Barton Frank; Jeanette Osban; Trevor M Penning; Hsueh-Kung Lin
Journal:  Prostate       Date:  2009-07-01       Impact factor: 4.104

8.  Genome-wide association study identifies genetic determinants of urine PCA3 levels in men.

Authors:  Zhuo Chen; Jielin Sun; Seong-Tae Kim; Jack Groskopf; Junjie Feng; William B Isaacs; Roger S Rittmaster; Lynn D Condreay; Siqun Lilly Zheng; Jianfeng Xu
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

9.  Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.

Authors:  Lucy J Schmidt; Kevin M Regan; S Keith Anderson; Zhifu Sun; Karla V Ballman; Donald J Tindall
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

Review 10.  Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.

Authors:  Elahe A Mostaghel
Journal:  Int J Biol Sci       Date:  2014-06-03       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.